Salarius Pharmaceuticals, Inc. and VolitionRx Limited announced the signing of a research and development collaboration to advance rapid epigenetic profiling using Volition's Nu.Q(R) technology to support further development of Salarius' clinical stage drug, seclidemstat. Seclidemstat, a novel oral, reversible, targeted LSD1 inhibitor that affects gene expression, is currently in Phase 1/2 clinical studies for solid and hematologic cancers where LSD1 is implicated in disease progression. Nu.Q(R) has been developed as simple, easy-to-use, cost-effective blood tests to diagnose and monitor a range of life-altering diseases including cancer in humans and animals.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4782 USD | +0.91% | -3.28% | -26.42% |
03-25 | Wall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation Data | MT |
03-25 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.42% | 2.26M | |
+69.81% | 62.86B | |
-0.70% | 41.38B | |
+45.66% | 40.38B | |
-10.72% | 27.64B | |
+14.30% | 26.46B | |
-22.28% | 18.9B | |
+4.83% | 12.67B | |
+23.77% | 12.27B | |
+28.25% | 12.07B |
- Stock Market
- Equities
- SLRX Stock
- News Salarius Pharmaceuticals, Inc.
- Salarius Pharmaceuticals and VolitionRx Enters into Research and Development Collaboration Agreement